Cancer NetworkOriginal article
<![CDATA[Ivonescimab/Chemotherapy Maintains OS Benefit in EGFR-Mutant NSCLC]]>
Phase 3positiveIvonescimabChemotherapyPositive
AI Analysis
Summary
Updated Phase 3 HARMONi trial data demonstrate that ivonescimab combined with chemotherapy maintains overall survival benefit in both Western and Asian patient populations with EGFR-mutant non-small cell lung cancer.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Ivonescimab plus chemotherapy maintains overall survival benefit in Western and Asian EGFR-mutant NSCLC patient groups
Importance:7/10
Sentiment:
0.75
NSCLCEGFR-mutationoverall survivalHARMONi trialchemotherapy combination
Read the original article
Published by Cancer Network on July 22, 2026 3:00 PM